GENinCode's (GENI's) portfolio of clinical genomic tests provides information to enhance standard risk assessment and diagnosis of cardiovascular disease (CVD), which is the highest cause of death globally (over 18 million deaths per annum) and the single-biggest area where the NHS can save lives over the next 10 years. GENI commercialises its tests, based on polygenic or multi-gene markers, in Europe and the UK. After generating H1 2022 revenues of £0.7m (+11%), end June cash of £12.4m covers g ....
27 Sep 2022
WH Ireland: GENinCode (GENI) - Advancing genetic risk assessment of cardiovascular disease
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
WH Ireland: GENinCode (GENI) - Advancing genetic risk assessment of cardiovascular disease
GENinCode PLC (GENI:LON) | 8.8 0 0.0% | Mkt Cap: 15.5m
- Published:
27 Sep 2022 -
Author:
Emma Ulker -
Pages:
30
GENinCode's (GENI's) portfolio of clinical genomic tests provides information to enhance standard risk assessment and diagnosis of cardiovascular disease (CVD), which is the highest cause of death globally (over 18 million deaths per annum) and the single-biggest area where the NHS can save lives over the next 10 years. GENI commercialises its tests, based on polygenic or multi-gene markers, in Europe and the UK. After generating H1 2022 revenues of £0.7m (+11%), end June cash of £12.4m covers g ....